What is QNCX's P/E ratio?

Quince Therapeutics, Inc. (QNCX) currently trades at a P/E ratio of 0.75.

Quince Therapeutics, Inc. reports a Return on Equity (ROE) of -210.80%.

What is QNCX's dividend yield?

Quince Therapeutics, Inc. offers a dividend yield of 0.00%.

What is QNCX's Quality Score?

Our AI rates QNCX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy QNCX?

Our AI Timing Score for QNCX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does QNCX belong to?

Quince Therapeutics, Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Quince Therapeutics, Inc. (QNCX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

QNCX AI Analysis Summary

Our AI summary for QNCX: Quince Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.75, ROE of -210.80%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

QNCX

Quince Therapeutics, Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 89

USD 28.88

1.47 (5.36%) Day Change

Watchlist Portfolio Compare Chart

0.75

P/E

0.01

D/E

-210.8%

ROE

-124.1%

ROA

0.00%

Div Yield

QUINCE THERAPEUTICS, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 28.88 Price 1.47 (5.36%) Day Change	NEWS SCORE: 89

QNCX, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	89
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	28.88
PBV / Sector	1.71 / 44,105.10
Earning Per Share	-35.59

PE / Sector	0.75 / 19.37 GREAT
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.82 M GREAT
Average 1W Daily Value	1.10 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-124.09 / 185,260.64
ROA Average (%) / Sector	-66.13 / 36,684.64
ROA Change Average (%) / Sector	59.79 / 422,221.42 GREAT
ROE (%) / Sector	-210.80 / 243,761.81
ROE Average (%) / Sector	-50.48 / 48,758.38
ROE Change Average (%) / Sector	-7.88 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:33
Symbol	QNCX
Name	QUINCE THERAPEUTICS, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	0.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	26.81 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

Phone: 415 910 5717

Website: https://quincetx.com

Sector: Healthcare >> Biotechnology

Description: Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.